HER2 Vaccine for Locally Advanced Breast Cancer
This study is testing an investigational vaccine, MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines, to see if it can help your immune system fight HER2-positive breast cancer. Researchers want to understand if the vaccine is safe and how well it activates the immune system. You may be able to join if you are 18 or older and have HER2-positive breast cancer. The study aims to enroll 36 participants. The current status of this study is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 36 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and immune response will be evaluated through the completion of 3 vaccine series, which is up to day 64 after the final vaccine injection.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
HER2 Vaccine for Locally Advanced Breast Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Pravin Kaumaya, PhD · PRINCIPAL_INVESTIGATOR · Indiana University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Evaluation of safety and toxicity at regular intervals by NCI common toxicity criteria 5.0through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection)
Number of adverse events as assessed by the NCI CTCAE v. 5.0
- Immune Responsethrough completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection)
Humoral immune response will be measured by ELISA quantification of IgM and IgG antibodies to HER2 (597-626) and HER2 (266-296).